Quantifying the Cardiovascular and Immunologic Changes after Spinal Cord Injury to Aid Diagnosis of Clinically Meaningful Infections

量化脊髓损伤后的心血管和免疫变化,以帮助诊断有临床意义的感染

基本信息

  • 批准号:
    10380502
  • 负责人:
  • 金额:
    $ 16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-01 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

7. Project Summary/Abstract Urinary tract infection (UTI, including catheter-associated UTI), is consistently amongst the top three reasons for health care use for persons with spinal cord injury (SCI), with a yearly cost of over $2 billion, not to mention the significant impact of the condition on quality of life. While the importance of recognizing and treating true UTI is evident, distinguishing this condition from asymptomatic bacteriuria (ASB, a positive urine culture without clinical signs or symptoms of infection) is particularly challenging after SCI due to the impaired ability to sense the most common signs and symptoms used in UTI diagnosis. This often leads to subjective interpretations of UTI signs and symptoms by patients and SCI providers alike. Bladder instrumentation with either indwelling or intermittent catheterization is often necessary after SCI to safely eliminate urine and maintain continence, however leads to high rates of ASB that do not need to be treated. Inappropriate treatment of ASB with antibiotics leads to the development of multi-drug resistant organisms, which are higher in persons with SCI than their age and co-morbidity-matched cohorts, conveying high morbidity and mortality. A possible solution to this conundrum is a diagnostic support tool for UTI after SCI; previously successful tools measure the degree of abnormality of multiple physiologic variables to measure the severity of acute disease. To calculate the degree of abnormality, however, we must have a better sense of the normal values for vital sign measurements and common laboratory studies for the SCI patient population. Therefore, the aims of this study are to 1) Establish the association between chronic SCI and baseline vital sign and lab measurements through a case-control study utilizing national Veterans Health Administration (VHA) data sources; and 2) Determine the positive predictive value of a constellation of physiologic variables defined as a screening tool for severe UTI after SCI through a retrospective cohort study. The data obtained from this study will support a NIH R01 proposal aimed to externally validate and assess the performance of the severe UTI screening tool prospectively. The assembled study team and environment are uniquely suited to completing this work, and have the support of clinical, research, administrative and patient advocacy leadership locally and nationally. This project supports the NICHD/NCMRR priority of identifying and treating secondary conditions associated with disability.
7。项目摘要/摘要 尿路感染(包括导管相关的UTI)始终是最高的三个原因之一 用于脊髓损伤患者(SCI)的医疗保健使用,每年成本超过20亿美元,更不用说 条件对生活质量的重大影响。而认识和对待真实的重要性 UTI显而易见,将这种情况与无症状细菌区分开 由于能力受损,因此没有临床体征或感染症状)特别具有挑战性 感觉在UTI诊断中使用的最常见的体征和症状。这通常会导致主观 患者和SCI提供者对UTI体征和症状的解释。带有膀胱仪器 SCI后通常需要留置或间歇性导管插入术才能安全消除尿液和 保持持续性,但是导致不需要治疗的ASB率很高。不当 用抗生素治疗ASB会导致多药耐药生物的发展,这些生物较高 在患有SCI的人中,其年龄和合并症匹配的人群传达了高发病率和死亡率。 解决此难题的可能解决方案是SCI后UTI的诊断支持工具。以前成功的工具 测量多个生理变量的异常程度,以衡量急性疾病的严重程度。 但是,要计算异常程度,我们必须更好地了解生命的正常值 SCI患者人群的标志测量和常见实验室研究。因此,目的 研究是1)建立慢性SCI与基线生命体征与实验室测量之间的关联 通过一项利用国家退伍军人卫生管理局(VHA)数据来源的案件对照研究;和2) 确定定义为筛选工具的生理变量星座的正预测值 通过回顾性队列研究,SCI后严重的UTI。从这项研究获得的数据将支持 NIH R01提案旨在外部验证和评估严重的UTI筛选工具的性能 前瞻性。组装的学习团队和环境非常适合完成这项工作,并且 在本地和全国范围内得到临床,研究,行政和患者倡导领导的支持。 该项目支持识别和治疗相关条件的NICHD/NCMRR优先级 残疾。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Felicia Skelton其他文献

Felicia Skelton的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Felicia Skelton', 18)}}的其他基金

Quantifying the Cardiovascular and Immunologic Changes after Spinal Cord Injury to Aid Diagnosis of Clinically Meaningful Infections
量化脊髓损伤后的心血管和免疫变化,以帮助诊断有临床意义的感染
  • 批准号:
    10577881
  • 财政年份:
    2022
  • 资助金额:
    $ 16万
  • 项目类别:
Optimizing Bacteriuria Management in Veterans with Spinal Cord Injury
优化脊髓损伤退伍军人的菌尿管理
  • 批准号:
    10308486
  • 财政年份:
    2017
  • 资助金额:
    $ 16万
  • 项目类别:

相似国自然基金

影像组学用于急性病毒性肺炎鉴别诊断的生物学机制探究
  • 批准号:
    82172029
  • 批准年份:
    2021
  • 资助金额:
    55.00 万元
  • 项目类别:
    面上项目
影像组学用于急性病毒性肺炎鉴别诊断的生物学机制探究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
胆碱能抗炎通路调节巨噬细胞M1/M2极化在CVB3诱导的急性病毒性心肌炎中的作用及机制研究
  • 批准号:
    81870281
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
急性病毒感染中转录因子Tbet对TFH应答的调控及机制研究
  • 批准号:
    31700774
  • 批准年份:
    2017
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
调控巨噬细胞极化的microRNA分子鉴定及其在CVB3诱导的急性病毒性心肌炎中的作用
  • 批准号:
    81472017
  • 批准年份:
    2014
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目

相似海外基金

Plasma Protein Biomarker-Based Diagnostics of Outcome in Sepsis and CAP
基于血浆蛋白生物标志物的脓毒症和 CAP 结果诊断
  • 批准号:
    8053158
  • 财政年份:
    2010
  • 资助金额:
    $ 16万
  • 项目类别:
Comparative Evaluation of Urinary Biological Markers for the Prognostic Stratific
尿液生物标志物预后分层的比较评估
  • 批准号:
    7585716
  • 财政年份:
    2008
  • 资助金额:
    $ 16万
  • 项目类别:
Comparative Evaluation of Urinary Biological Markers for the Prognostic Stratific
尿液生物标志物预后分层的比较评估
  • 批准号:
    7388341
  • 财政年份:
    2008
  • 资助金额:
    $ 16万
  • 项目类别:
Plasma Protein Biomarker-Based Diagnostics of Outcome in Sepsis and CAP
基于血浆蛋白生物标志物的脓毒症和 CAP 结果诊断
  • 批准号:
    7661428
  • 财政年份:
    2005
  • 资助金额:
    $ 16万
  • 项目类别:
Plasma Protein Biomarker-Based Diagnostics Of Outcome In Sepsis and CAP
基于血浆蛋白生物标志物的脓毒症和 CAP 结果诊断
  • 批准号:
    7286345
  • 财政年份:
    2005
  • 资助金额:
    $ 16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了